201. Antimüllerian hormone levels decrease in women using combined contraception independently of administration route.
- Author
-
Kallio S, Puurunen J, Ruokonen A, Vaskivuo T, Piltonen T, and Tapanainen JS
- Subjects
- Administration, Cutaneous, Adult, Contraceptive Devices, Female, Desogestrel administration & dosage, Drug Combinations, Estrogens administration & dosage, Ethinyl Estradiol administration & dosage, Female, Follicle Stimulating Hormone, Human blood, Humans, Norgestrel administration & dosage, Norgestrel analogs & derivatives, Oximes administration & dosage, Prospective Studies, Young Adult, Anti-Mullerian Hormone blood, Contraceptives, Oral, Combined administration & dosage, Ovarian Follicle drug effects, Pituitary Gland drug effects
- Abstract
Objective: To compare the effects of continuous use of oral (OC), transdermal, and vaginal combined contraceptives on the pituitary-ovarian axis and inhibition of follicular development., Design: Spin-off study of a prospective, randomized trial., Setting: University clinic., Patient(s): Forty-two of 54 healthy women completed the study., Intervention(s): Treatment with combined OCs (ethinyl E2 [EE] and desogestrel), transdermal patches (EE and norelgestromin), or vaginal rings (EE and etonogestrel) for 9 weeks continuously. Blood sampling was performed before and at 5 and 9 weeks of treatment., Main Outcome Measure(s): Changes in serum hormone levels induced by combined contraceptives., Result(s): Serum antimüllerian hormone (AMH), FSH, inhibin B, LH, and E2 levels had decreased significantly in all study groups after 9 weeks of treatment. Significant declines were already detected after 5 weeks' use of combined contraceptives with regard to all hormone levels apart from those of serum AMH, where the decrease between baseline and 5 weeks was only moderate. Between groups, serum levels of AMH, inhibin B, LH, and E2 were comparable at baseline and after 5 and 9 weeks of treatment., Conclusion(s): The decrease of serum AMH levels during the use of all combined contraceptives indicates that folliculogenesis is arrested independently of administration route., Clinical Trial Registration Number: NCT01087879., (Copyright © 2013 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF